<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1052">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04528901</url>
  </required_header>
  <id_info>
    <org_study_id>7879</org_study_id>
    <nct_id>NCT04528901</nct_id>
  </id_info>
  <brief_title>Study of seroPREvalence Vis-à-vis SARS-CoV2 and Correlation With Clinical Forms of COVID-19 in Patients Followed in Pneumology in the Cluster Area of the Grand-Est Region (Strasbourg University Hospital)</brief_title>
  <acronym>PRESAGE</acronym>
  <official_title>Study of seroPREvalence Vis-à-vis SARS-CoV2 and Correlation With Clinical Forms of COVID-19 in Patients Followed in Pneumology in the Cluster Area of the Grand-Est Region (Strasbourg University Hospital)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      seroPREvalence vis-à-vis SARS-CoV2 and correlation with clinical forms of COVID-19 in
      patients followed in Pulmonology in the cluster area of the Grand-Est region.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine and compare the seroprevalence for SARS-CoV2 among patients with respiratory pathologies monitored in Pneumology at the Strasbourg University Hospital, in the cluster zone of the Grand Est.</measure>
    <time_frame>15 months</time_frame>
    <description>Carrying out a serological assay of specific antibodies to SARS-CoV-2</description>
  </primary_outcome>
  <enrollment type="Anticipated">1080</enrollment>
  <condition>Covid-19</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patient followed in pulmonology at Strasbourg University Hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman from 18 years old and without upper age limit

          -  Patient followed in pulmonology at Strasbourg University Hospital

          -  Patient presenting at least one of the following pathologies:

               1. severe persistent asthma (200 patients)

               2. chest cancer that is active or has received treatment within a period of less
                  than one year (300 patients)

               3. history of lung transplantation performed before the start of the epidemic
                  (02/29/2020) (300 patients)

               4. idiopathic or other diffuse interstitial lung disease, sarcoidosis or vasculitis
                  (70 patients)

               5. pulmonary arterial hypertension (PAH) (group 1 of the international
                  classification) any cause or chronic thromboembolic PAH (group 4): (60 patients)

               6. Severe COPD in the respiratory failure stage (150 patients)

          -  Subject affiliated to a social health insurance protection scheme

          -  Subject able to understand the objectives of the research

          -  Subject having signed an informed consent

        Exclusion Criteria:

          -  Inability to provide informed information about the subject (subject in an emergency
             situation, difficulty in understanding the subject, etc.)

          -  Subject under safeguard of justice

          -  Subject under guardianship or guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Céline MASCAUX</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Céline MASCAUX</last_name>
    <phone>+ 3 33 69 55 06 44</phone>
    <email>Celine.mascaux@chru-strabourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Les Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <state>Bas-Rhin</state>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Céline MASCAUX</last_name>
      <phone>+33 3 69 55 06 44</phone>
      <email>Celine.mascaux@chru-strabourg.fr</email>
    </contact>
    <investigator>
      <last_name>Céline MASCAUX</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>August 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

